Key Points
- CEO Lawrence Klein sold 25,000 Oruka Therapeutics shares at an average price of $83.62, generating $2.09 million. The transaction was executed under a pre-arranged Rule 10b5-1 plan and reduced his direct ownership by 2.64% to 923,128 shares.
- Oruka shares opened at $84.52 and have a market capitalization of approximately $5.60 billion, while the company recently reported a quarterly loss of $0.55 per share, missing the consensus estimate of $0.51.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $128.91 price target; institutional investors own 56.44% of the stock.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) CEO Lawrence Klein sold 25,000 shares of the firm's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $83.62, for a total value of $2,090,500.00. Following the transaction, the chief executive officer directly owned 923,128 shares in the company, valued at $77,191,963.36. This trade represents a 2.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Lawrence Otto Klein also recently made the following trade(s):
- On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $234,680.92.
- On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00.
Oruka Therapeutics Stock Up 1.3%
Shares of ORKA opened at $84.52 on Friday. The firm has a 50-day moving average price of $95.77 and a 200 day moving average price of $77.45. The firm has a market capitalization of $5.60 billion, a PE ratio of -41.64 and a beta of -0.37. Oruka Therapeutics, Inc. has a 52-week low of $19.04 and a 52-week high of $115.51.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities analysts expect that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.
Institutional Investors Weigh In On Oruka Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of ORKA. Sei Investments Co. boosted its position in shares of Oruka Therapeutics by 136.0% in the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company's stock valued at $1,120,000 after purchasing an additional 13,164 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Oruka Therapeutics during the 1st quarter worth about $5,543,000. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $2,874,000. Handelsbanken Fonder AB acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $15,313,000. Finally, Braidwell LP purchased a new stake in Oruka Therapeutics during the second quarter valued at about $26,473,000. 56.44% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ORKA has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Weiss Ratings upgraded Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 15th. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. Wedbush set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 24th. Finally, Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Oruka Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $128.91.
View Our Latest Report on ORKA
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.
Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
